Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary alveolar proteinosis.

O C Ioachimescu1, M S Kavuru

  • 1Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic Foundation, A90, Cleveland, OH 44195, USA. oioac@yahoo.com

Chronic Respiratory Disease
|August 19, 2006
PubMed
Summary

Pulmonary alveolar proteinosis involves surfactant buildup in the lungs. Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy shows promise for acquired forms, but congenital types do not respond.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

The European respiratory journal·2011
Same author

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.

The European respiratory journal·2008
Same author

Hepatopulmonary syndrome following portopulmonary hypertension.

The European respiratory journal·2007
Same author

From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung.

The European respiratory journal·2005
Same author

Genome-wide search for sarcoidosis susceptibility genes in African Americans.

Genes and immunity·2005
Same author

Idiopathic pulmonary haemosiderosis revisited.

The European respiratory journal·2004

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Genetics

Background:

  • Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation.
  • It presents with variable clinical courses, ranging from spontaneous resolution to fatal respiratory failure.
  • Current standard treatment involves whole lung lavage.

Purpose of the Study:

  • To review recent advancements in understanding PAP pathogenesis and therapy.
  • To explore the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in PAP.
  • To differentiate therapeutic approaches for acquired and congenital PAP forms.

Main Methods:

  • Review of recent scientific literature on PAP pathogenesis and treatment.
  • Analysis of the role of GM-CSF pathway and anti-GM-CSF autoantibodies.
  • Examination of genetic defects in congenital PAP.

Main Results:

  • The GM-CSF pathway is implicated in both acquired and congenital PAP.
  • Anti-GM-CSF autoantibodies are found in acquired PAP, potentially impairing surfactant clearance.
  • Congenital PAP is linked to mutations in GM-CSF receptor or surfactant protein genes.
  • GM-CSF therapy is effective in approximately half of acquired PAP cases.
  • Congenital PAP does not respond to GM-CSF therapy.

Conclusions:

  • GM-CSF is a potential therapeutic agent for acquired PAP, but its optimal use requires further study.
  • Understanding the specific pathogenic mechanisms is crucial for tailoring treatment strategies.
  • Genetic defects define congenital PAP and explain its lack of response to GM-CSF.
  • Further research is needed to elucidate anti-GM-CSF antibody dynamics and GM-CSF dosing in acquired PAP.

Related Experiment Videos